Comparing biological markers of Alzheimer’s disease across blood fraction and platforms: Comparing apples to oranges Page: 27
8 p.View a full description of this article.
Extracted Text
The following text was automatically extracted from the image on this page using optical character recognition software:
Alzheimer's
CrossMark
Dementia
ELSEVIER Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 3 (2016) 27-34
Blood-Based Biomarkers
Comparing biological markers of Alzheimer's disease across blood
fraction and platforms: Comparing apples to oranges
Sid E. O'Bryanta'*, Simone Listab'c, Robert A. Rissmand, Melissa Edwardse, Fan Zhangf,
James Hallag, Henrik Zetterberghi, Simon Lovestone&, Veer Guptak, Neill Graff-Radford',
Ralph Martinsk, Andreas Jerominm, Stephen Waring"'0, Esther Oh, Mitchel Kingq,
Laura D. Bakery, Harald Hampelb'c, for the ISTAART Blood Based Biomarker Professional
Interest Area
aInstitute for Healthy Aging, Center for Alzheimer's & Neurodegenerative Disease Research, University of North Texas Health Science Center TX, USA
hAXA Research Fund & UPMC Chair Paris, France
cSorbonne Universites, University Pierre et Marie Curie, Paris 06, Institut de la Mmoire et de la Maladie d'Alzheimer (IM2A) & Institut du Cerveau et de la
Moelle epiniere (ICM), Dpartement de Neurologie, Hopital de la Piti-Salpetriere, Paris, France
dAlzheimer's Disease Cooperative Study, Department of Neurosciences, UCSD School of Medicine, La Jolla, CA, USA
eDepartment of Psychology, University of North Texas, Denton, TX, USA
1Department of Molecular and Medical Genetics, University of North Texas Health Science Center, Fort Worth, TX, USA
'Department of Psychiatry, University of North Texas Health Science Center Fort Worth, TX, USA
hClinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mblndal, Sweden
'UCL Institute of Neurology, London, UK
'Department of Psychiatry, University of Oxford, Oxford, UK
kCenter of Excellence for Alzheimer's Disease Research and Care, School of Medical Sciences, Faculty of Health, Engineering and Sciences, Edith Cowan
University, Joondalup, WA, Australia
'Department of Neurology, Mayo Clinic, Jacksonville, FL, USA
'mQuanterix Corp., Lexington, MA, USA
"Essentia Institute of Rural Health, Duluth, MN, USA
"Texas Alzheimer's Research and Care Consortium, TX, USA
"Division of Geriatric Medicine and Gerontology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
'Behavioral Health Service, Cpl. Michael J. Crescenz VA Medical Center and Department of Psychiatry, Perelman School of Medicine at the University of
Pennsylvania, Philadelphia, PA, USA
'Department of Medicine, Internal Medicine (Geriatrics), Wake Forest School of Medicine, Winston Salem, NC, USA
Abstract Introduction: This study investigated the comparability of potential Alzheimer's disease (AD) bio-
markers across blood fractions and assay platforms.
Methods: Nonfasting serum and plasma samples from 300 participants (150 AD patients and 150
controls) were analyzed. Proteomic markers were obtained via electrochemiluminescence or Lumi-
nex technology. Comparisons were conducted via Pearson correlations. The relative importance of
proteins within an AD diagnostic profile was examined using random forest importance plots.
Results: On the Meso Scale Discovery multiplex platform, 10 of the 21 markers shared >50% of the
variance across blood fractions (serum amyloid A R2 = 0.99, interleukin (IL)10 R2 = 0.95, fatty acid-
binding protein (FABP) R2 = 0.94, 1309 R2 = 0.94, IL-5 R2 = 0.94, IL-6 R2 = 0.94, eotaxin3
R2 = 0.91, IL-18 R2 = 0.87, soluble tumor necrosis factor receptor 1 R2 = 0.85, and pancreatic poly-
peptide R2 = 0.81). When examining protein concentrations across platforms, only five markers
S.E.O. has multiple patients pending, submitted by the University of S.L., R.A.R., M.E., F.Z., J.H., H.Z., S.L., V.G., N.G.-R., R.M., S.W., E.O.,
North Texas Health Science Center wherein he is an inventor and receives M.K., L.B., and H.H. report no conflicts of interests.
research grants from the National Institutes of Health, National Institute *Corresponding author. Tel.: +1-817-735-2961; Fax: +1-817-735-
on Aging, award number R01AG039389 and P30AG12300. A.J. holds affil- 0611.
iations with Atlantic Biomarkers, LLC and reports no conflict of interests. E-mail address: Sid.O'Bryant@unthsc.eduhttp://dx.doi.org/10.1016/j.dadm.2015.12.003
2352-8729/ 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer's Association. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Upcoming Pages
Here’s what’s next.
Search Inside
This article can be searched. Note: Results may vary based on the legibility of text within the document.
Tools / Downloads
Get a copy of this page or view the extracted text.
Citing and Sharing
Basic information for referencing this web page. We also provide extended guidance on usage rights, references, copying or embedding.
Reference the current page of this Article.
O'Bryant, Sid E.; Lista, Simone; Rissman, Robert A.; Edwards, Melissa; Zhang, Fan; Hall, James R. et al. Comparing biological markers of Alzheimer’s disease across blood fraction and platforms: Comparing apples to oranges, article, December 29, 2015; Amsterdam, The Netherlands. (https://digital.library.unt.edu/ark:/67531/metadc1132747/m1/1/: accessed July 18, 2024), University of North Texas Libraries, UNT Digital Library, https://digital.library.unt.edu; crediting UNT College of Arts and Sciences.